Home » Newsletters » BioWorld Science

BioWorld Science

March 13, 2007

View Archived Issues

Natural toxin shows potential against prostate cancer in vitro

New agents for treating acne and alopecia reported in recent Pfizer patent

Recent patents describe novel therapeutic agents for respiratory disorders

Novel treatment option for irritable bowel syndrome disclosed by Astellas

Identification of c-Src protein kinase inhibitors as a novel class for anti-dengue virus therapy

Anti-ribosomal P antibodies may explain CNS symptoms in SLE

Aeterna Zentaris rounds up 2006 clinical progress

Formulation work required for CRD-5 following phase I/II findings

Peplin updates progress of PEP-005 Topical program

Studies show Radilex may stimulate hematopoietic stem cells

TM-30339 advanced into clinical trials for obesity

Positive data reported from phase Ib study of TASQ

Oxford BioMedica to acquire Oxxon Therapeutics

Schering-Plough to acquire Organon Biosciences

Sym-001, first recombinant polyclonal antibody to enter clinical trials

Array BioPharma reports on anticancer activity of its p38 MAPK inhibitor

Biomarker studies test AZD-0530's potential in managing bone metastasis

Cardium Therapeutics closes private placement financing

FDA updates safety information for erythropoiesis-stimulating agents

Pemetrexed combinations found highly effective against NSCLC cells

SNS-314 shows consistent and dose-dependent antitumor activity in mice

WX-671 plus 5-FU, gemcitabine or irinotecan reduce cancer metastasis and invasion

Nitoman launched in Germany

Xyrem approved in E.U. for narcolepsy with cataplexy

Approvable letter for Accretropin

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
Autobahn on the fast track with bipolar thyroid agonist
BioWorld
Achieving high marks in the phase II Amplify-BD trial for bipolar I and II depression, Autobahn Therapeutics Inc.’s elunetirom, a brain-penetrant central nervous...